Elanco Animal Health Incorporated announced on July 9, 2025, that the U.S. Department of Agriculture (USDA) has approved TruCan Ultra CIV H3N2/H3N8. This canine influenza vaccine is designed to provide broad respiratory disease protection for dogs.
The approval of TruCan Ultra CIV completes Elanco's Tru Portfolio of comfortable and convenient combination vaccines. These vaccines are made with PureFil Technology, an exclusive process aimed at creating highly purified vaccines to reduce adverse reactions and deliver better experiences for pets.
This new vaccine strengthens Elanco's offerings in the pet health segment, providing veterinarians with an additional tool to protect dogs against serious respiratory diseases. The expansion of its vaccine portfolio contributes to Elanco's strategy of delivering high-impact innovation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.